Avadel Pharmaceuticals plc(US:AVDL)2025-05-07 12:03Financial Performance & Guidance - Avadel Pharmaceuticals generated $52.5 million in net revenue in Q1 2025, a 93% increase year-over-year[11] - The company raised FY25 revenue guidance to $255 - $265 million, previously $240 - $260 million[12] - Q2 2025 revenue guidance is $60 - $63 million[12] - FY25 cash flow guidance was raised to $30 - $40 million, previously $20 - $40 million[12] - The company had $66.5 million of cash, cash equivalents, and marketable securities as of March 31, 2025[12] LUMRYZ Commercialization - Approximately 2,800 patients are currently on LUMRYZ therapy, with a net increase of 300 patients in Q1 2025[7, 11] - The company raised guidance for patients on therapy to 3,400 – 3,600 by the end of 2025, previously 3,300 – 3,500[11] - Reimbursed patients on therapy as of March 31, 2025, are over 2,000[19] - The company estimates LUMRYZ peak sales opportunity is greater than $1 billion for narcolepsy[16] Clinical Development - Enrollment remains robust in the Phase 3 REVITALYZ trial for Idiopathic Hypersomnia (IH), with completion expected in Q4 2025[11, 20] - The REVITALYZ trial targets approximately 150 patients for a 14-week period[20] - Approximately 10% of the 42,000 diagnosed IH patients in the US are treated with the only FDA-approved oxybate treatment[20]